Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2025 ,inter alia, to consider and approve a) The Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025, along with the Statement of Assets and Liabilities, Cash Flow Statement, and take note of the Audit Report with modified opinion, if any, thereon.\r\nb) The Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2025, and\r\nc) Recommend the Final Dividend, if any, for the financial year ended March 31, 2025